Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 0.77 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.76 |
| ▸ | INSR | P06213 | 3/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | BUB1B | O60566 | 1/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | NPM1 | P06748 | 1/20 | 0.68 |
| ▸ | FES | P07332 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | IGF1R | P08069 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | ROS1 | P08922 | 1/20 | 0.68 |
| ▸ | FGR | P09769 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21846990 | 0.87 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL24852882 | 0.87 | ALK (1.00) | EGFRMETALKINSRKCNH2 | |
| SCHEMBL26611562 | 0.85 | EGFR (0.74) | EGFRMETALKINSRKCNH2 | |
| SCHEMBL20490720 | 0.84 | ALK (0.81) | EGFRMETALKINSRKCNH2 | |
| SCHEMBL23637757 | 0.83 | ALK (0.87) | EGFRMETALKINSRKCNH2 | |
| SCHEMBL21099490 | 0.82 | EGFR (0.69) | EGFRMETALKPTK2 | |
| SCHEMBL15977109 | 0.82 | ALK (0.80) | EGFRMETALKINSRKCNH2 | |
| SCHEMBL21169823 | 0.81 | ALK (0.86) | EGFRMETALKINSRKCNH2 | |
| Ceritinib SCHEMBL1014329 | 0.81 | ALK (1.00) | EGFRMETALKINSRKCNH2 | |
| Ceritinib SCHEMBL29489147 | 0.81 | ALK (1.00) | EGFRMETALKINSRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640246-B1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-11-01 | — | — | EP | claimed |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-08-11 | — | — | US | claimed |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-02-22 | — | — | US | claimed |
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-11 | — | — | US | claimed |
| EP-3640246-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2020-04-22 | — | — | EP | claimed |
| CN-110740999-A | N2, N4-diphenylpyrimidine-2, 4-diamine derivative, process for producing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2020-01-31 | — | — | CN | claimed |
| EP-3640246-B1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-11-01 | — | — | EP | disclosed |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-08-11 | — | — | US | disclosed |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-02-22 | — | — | US | disclosed |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-02-22 | — | — | US | disclosed |
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-11 | — | — | US | disclosed |
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-11 | — | — | US | disclosed |
| EP-3640246-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2020-04-22 | — | — | EP | disclosed |
| CN-110740999-A | N2, N4-diphenylpyrimidine-2, 4-diamine derivative, process for producing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2020-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | FLT3, EGFR, ERBB2 | EGFR 2/4885MET 169/4885ALK 76/4885 |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | FLT3, EGFR, ERBB2 | EGFR 2/4885MET 169/4885ALK 76/4885 |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | FLT3, EGFR, ERBB2 | EGFR 2/4885MET 169/4885ALK 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.